Top Markets
Coin of the day
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SOBI
Peringkat dalam Saham #1381
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in... Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.
Harga Saham
$49.68
Terakhir disinkronkan: 2026-08-12
Kapitalisasi Pasar
$17.25B
Perubahan (1 hari)
0.77%
Perubahan (1 tahun)
72.21%
Negara
SE
Perdagangan Swedish Orphan Biovitrum AB (SOBI)

Kategori

Riwayat pemecahan saham untuk Swedish Orphan Biovitrum AB (SOBI)
Saham Swedish Orphan Biovitrum AB (simbol: SOBI) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Aug 13, 2026.
Satu lembar saham SOBI yang dibeli sebelum Aug 13, 2026 sekarang setara dengan 0 lembar saham SOBI.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing